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Drawing
Comparisons
at Duke
Comparative genomics is the study of
genomes from different species in order to
better understand how species have
evolved and what the functions are of
both genes and noncoding sections of the
genome. As part of the NIEHS
Toxicogenomics Research Consortium
(TRC), researchers at the Duke Center
for Environmental Genomics are focusing
on comparative genomics as a way to
explore how environmental stresses affect
human health.
The NIEHS established the TRC in
November 2001 to serve as the extramural
mechanism by which the NCT applies
microarray technology. Funded at $37
million over five years, the TRC is a coor-
dinated, multidisciplinary effort between
the NIEHS Microarray Center and five
academic research institutions (Duke, the
University of North Carolina–Chapel Hill,
the Massachusetts Institute of Technology,
Oregon Health & Science University, and
the Fred Hutchinson Cancer Research
Center/University of Washington), along
with private companies contracted to assist
with microarray development and bioin-
formatics. The TRC is intended to signifi-
cantly advance the pace of discovery in
toxicogenomics, while simultaneously
accelerating the development and valida-
tion of microarray technology.
At roughly the halfway point of the
initial grant period, the TRC is already
bearing important scientific fruit and
appears poised to make substantial con-
tributions to the field as research sup-
ported by rapidly progressing technology
produces new insights into the complex
relationship between environmental
exposures and gene expression.
All the Organisms, Two by Two . . .
The Duke investigators believe that com-
parative genomics—the isolation and
identification of common, conserved
genomic responses across different model
species—will have a major impact on
advancing useful knowledge within the
field of toxicogenomics. The discipline
makes it possible to probe into the phylo-
genetic origins of gene families and how
they have been altered as species rose high-
er; eventually these gene structures and
relative functions can be compared to
those of humans, says NCT deputy direc-
tor James K. Selkirk. Part of the TRC’s
mission has been the development of
sophisticated, reliable microarrays of the
genomes of model systems such as
Caenorhabditis elegans, zebrafish, yeast,
and mouse, which allow rapid, high-
throughput screening across species in a
variety of areas of interest. 
Ongoing independent exploration by
Elwood Linney and Marcy Speer into the
genetics of neural tube development and
defects is a case in point. Microbiologist
Linney is working with zebrafish microar-
rays to identify sets of genes that might be
involved in embryonic neural tube devel-
opment, or disruption of normal develop-
ment by environmental insults. Those
candidate genes can then be used by
human geneticist Speer to screen within
subject families for polymorphisms that
might correlate with families with neural
tube defects such as spina bifida. 
Although they have already made sub-
stantial strides in the biology, Linney says,
“a major part of the progress to date has
been just the technology. When we start-
ed, there weren’t any microarrays for
zebrafish.” With the recent delivery of a
22,000-gene zebrafish microarray devel-
oped in cooperation with TRC contrac-
tors, “we’re ready to start generating a
variety of different types of data using per-
turbations of neural tube development,”
he says. 
Such large-scale genomic screening
lends itself to ferreting out the signaling
pathways that might be involved in toxic
response and repair mechanisms. Micro-
array technology allows researchers to cast
a big net over a problem, rather than
focusing on specific genes, says Linney.
Once patterns of expression are identified
via microarray, RNA interference (RNAi)
or morpholinos (another gene silencer) can
be applied to confirm the function of the
genes. “If we think a certain toxicant is
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.affecting a certain gene product, we can test
that by designing something to knock
down that gene product and see if we still
get the same phenotype,” he says.
TRC principal investigator David
Schwartz is using a similar comparative
genomics approach in his TRC indepen-
dent project. Schwartz is examining the
genes and genomic responses involved in
the immune response to bacterial toxins
such as endotoxin, which are released into
the bloodstream during bacterial infection
and can, in themselves, cause a variety of
symptoms. “We are using genomics as a
way of highlighting a number of genes that
we know are biologically related to the
immune response to bacterial toxins,” he
explains. This will help identify genes that
may have variants, some of which would
predispose individuals to experience
adverse responses when they have various
types of infection.
Schwartz’s group has identified a few
very promising candidates as a result of
studies with mouse microarrays. “We’ve
found specific areas of the genome that are
clearly associated with the biologic
response,” he says, “and we’ve found a cou-
ple that we think may be critical in terms of
regulating the response—genes that had not
previously been described as being impor-
tant or relevant to processing or responding
to bacterial toxins.” To further elucidate the
potential role of these genes, Schwartz’s
team is currently testing them in C. elegans,
as well as looking at loss of function by
using RNAi to downregulate their expres-
sion in mammalian cells. 
Jonathan Freedman, who heads up the
center’s Toxicology Core, is the group’s C.
elegans specialist. He is currently developing
a high-throughput worm genome–wide
microarray to screen compounds and devel-
op signature profiles of response to a variety
of toxicants, including bacterial toxins,
chemicals, metals, and alkylating agents.
He believes that such genomewide screen-
ing is the best way to extract useful infor-
mation. For example, he says, his group has
identified about 300 genes that are upregu-
lated in response to cadmium. “But we’re
not going to go through and look at each
gene,” he says. Instead, he plans to look at
the whole genome to study why cadmium
affects all 300 genes, then link that infor-
mation to what cadmium can do to cause
cancer and other diseases.
Evolution of a Field
Freedman is enthusiastic about the Duke
center’s comparative genomics focus. “We
definitely think that’s the way toxicoge-
nomics needs to evolve,” he says. “There’s
just so much power in a lot of these alterna-
tive species, especially yeast and C. elegans
and zebrafish. You can do rapid genetics,
very rapid RNAi types of studies, and you
can do a lot of linking to the genome.”
Besides his own work with C. elegans,
Freedman is also working collaboratively
with other member institutes on microarray
development and standardization, a crucial
issue within the field. Freedman and col-
leagues distributed material to each of the
labs to be used in their microarrays, to see
whether all the experiments would come
out with the same results. Freedman
reports that the first phase of this coopera-
tive work has been completed and is being
prepared for publication. The study
addressed the issue of data reproducibility
by standardizing gene expression experi-
ments across different labs and microarray
platforms. The TRC will continue its col-
laborative efforts at standardization with a
new project, possibly addressing compara-
tive genomics.
There should be very exciting results
emerging from the Duke center’s work in
the near future, and from the entire TRC’s
efforts as well. Schwartz cites three reasons
that the TRC initiative will ultimately
prove to be of great importance to toxi-
cogenomics: “One is that these approaches
will undoubtedly allow us to identify early
responses to toxic agents in the environ-
ment, and potentially identify individuals
before they develop disease. Secondly,
using genomics as a way of targeting genes
may allow us to short-circuit and hasten
the process of identifying which genetic
variants are related to susceptibility to
environmental agents. And thirdly, this
effort will allow us to more clearly pheno-
type diseases into biological categories of
disease, as opposed to clinical or physiolog-
ical categories of disease that oftentimes
lack precision.” –Ernie Hood
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